These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20059784)

  • 1. Coverage with Evidence Development: applications and issues.
    Trueman P; Grainger DL; Downs KE
    Int J Technol Assess Health Care; 2010 Jan; 26(1):79-85. PubMed ID: 20059784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology--part 2: coverage.
    Raab GG; Parr DH
    J Am Coll Radiol; 2006 Oct; 3(10):772-7. PubMed ID: 17412167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Authority for Health: France.
    Rochaix L; Xerri B
    Issue Brief (Commonw Fund); 2009 Jul; 58():1-9. PubMed ID: 19639712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A primer on the assessment of medical technologies.
    Matuszewski KA
    Pharm Pract Manag Q; 1997 Jan; 16(4):53-65. PubMed ID: 10164160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A successful practical application of Coverage with Evidence Development in Australia: Medical Services Advisory Committee interim funding and the PillCam Capsule Endoscopy Register.
    O'Malley SP; Selby WS; Jordan E
    Int J Technol Assess Health Care; 2009 Jul; 25(3):290-6. PubMed ID: 19619347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare and cost-effectiveness analysis.
    Neumann PJ; Rosen AB; Weinstein MC
    N Engl J Med; 2005 Oct; 353(14):1516-22. PubMed ID: 16207857
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction of emerging medical devices on the market: a new procedure in Belgium.
    Vinck I; Neyt M; Thiry N; Louagie M; Ramaekers D
    Int J Technol Assess Health Care; 2007; 23(4):449-54. PubMed ID: 17937833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technology assessment, coverage decisions, and conflict: the role of guidelines.
    Sheingold SH
    Am J Manag Care; 1998 Sep; 4 Spec No():SP117-25. PubMed ID: 10185988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coverage options for promising technologies: Medicare's 'coverage with evidence development'.
    Tunis SR; Pearson SD
    Health Aff (Millwood); 2006; 25(5):1218-30. PubMed ID: 16966717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics.
    Retèl VP; Bueno-de-Mesquita JM; Hummel MJ; van de Vijver MJ; Douma KF; Karsenberg K; van Dam FS; van Krimpen C; Bellot FE; Roumen RM; Linn SC; van Harten WH
    Int J Technol Assess Health Care; 2009 Jan; 25(1):73-83. PubMed ID: 19126254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach.
    Vallejo-Torres L; Steuten LM; Buxton MJ; Girling AJ; Lilford RJ; Young T
    Int J Technol Assess Health Care; 2008; 24(4):459-64. PubMed ID: 18828941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coverage with evidence development: an examination of conceptual and policy issues.
    Hutton J; Trueman P; Henshall C
    Int J Technol Assess Health Care; 2007; 23(4):425-32. PubMed ID: 17937829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?
    Pouwels XGLV; Grutters JPC; Bindels J; Ramaekers BLT; Joore MA
    Value Health; 2019 Jul; 22(7):799-807. PubMed ID: 31277827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
    Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
    Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.